HK Stock Market Move | Brain-machine interface concept stocks lead the decline, institutions say that in the short term, the commercialization of brain-machine interfaces will focus more on non-invasive methods.
Concept stocks of brain-machine interfaces lead the decline, as of the time of writing, Nanjing Panda Electronics Co., Ltd. (00553) fell by 8.29% to HKD 5.53; Blue Think Technology Co., Ltd. (06613) fell by 5.74% to HKD 28.26; BrainGo Aurora-B (06681) fell by 5.7% to HKD 7.11; MicroPort NeuroTech (02172) fell by 2.23% to HKD 13.15.
Concept stocks of brain-computer interfaces led the decline. As of the time of writing, NANJING PANDA (00553) fell by 8.29% to 5.53 Hong Kong dollars; Lens Technology (06613) fell by 5.74% to 28.26 Hong Kong dollars; BRAINAURORA-B (06681) fell by 5.7% to 7.11 Hong Kong dollars; MICROPORT NEURO (02172) fell by 2.23% to 13.15 Hong Kong dollars.
In terms of news, Nanjing Panda Electronics previously announced in a notice on abnormal stock price fluctuations that the company's main business focuses on smart transportation and safe cities, industrial Internet and smart manufacturing, and green service-oriented electronic manufacturing. As of now, the company has no mature products related to brain-computer interfaces and has not generated any related sales revenue, so the concept will not have a substantial impact on the company's current production and operation.
Wanlian Securities pointed out that in the short term, the commercialization of brain-computer interfaces is more focused on non-invasive methods, while in the medium to long term, the core lies in upstream technologies such as (semi-) invasive/invasive "flexible electrodes + high-throughput low-power chips", multicenter clinical trials, compliance standards, and other comprehensive system capabilities. Industry policy support, medical insurance payments, breakthroughs in registered clinical milestones, core technological breakthroughs, and domestic substitution are all future catalysts for industry development. Invasive methods focus on R&D teams, clinical resources, financing environment, etc.; non-invasive methods focus on branding, channels, and cost control.
Related Articles

Qingdao Vland Biotech INC. (603739.SH) has obtained a new animal drug registration certificate.

LUSTER LightTech (688400.SH) has obtained approval from the China Securities Regulatory Commission for its issuance of additional shares.

HAITONG INT'L: The growth rate of express delivery has slowed down, and anti-insulation measures will help repair industry profitability.
Qingdao Vland Biotech INC. (603739.SH) has obtained a new animal drug registration certificate.

LUSTER LightTech (688400.SH) has obtained approval from the China Securities Regulatory Commission for its issuance of additional shares.

HAITONG INT'L: The growth rate of express delivery has slowed down, and anti-insulation measures will help repair industry profitability.

RECOMMEND

Institutions Bullish On Hong Kong Stocks As Spring Rally Builds; Domestic And Foreign Capital Increase ETF Allocations
13/01/2026

The Sword Over Hong Kong Stocks: IPO Peaks And Unlocking Waves
13/01/2026

Learning From History: The AI Investment Wave Likely To End This Year, But The Fed May Shield U.S. Stocks
13/01/2026


